Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.

ABSTRACT:

Background

Prospective data on the risk of recurrence among women with hormone receptor-positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking.

Methods

We conducted a single-group trial in which we evaluated the temporary interruption of adjuvant endocrine therapy to attempt pregnancy in young women with previous breast cancer. Eligible women were 42 years of age or younger; had had stage I, II, or III disease; had received adjuvant endocrine therapy for 18 to 30 months; and desired pregnancy. The primary end point was the number of breast cancer events (defined as local, regional, or distant recurrence of invasive breast cancer or new contralateral invasive breast cancer) during follow-up. The primary analysis was planned

SUBMITTER: Partridge AH 

PROVIDER: S-EPMC10358451 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature